Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice.
Anti-angiogenic therapy
Atezolizumab
Bevacizumab
Child Pugh cirrhosis
Hepatocellular carcinoma
Immunotherapy
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Sep 2021
27 Sep 2021
Historique:
received:
07
04
2021
revised:
27
06
2021
accepted:
09
08
2021
entrez:
11
10
2021
pubmed:
12
10
2021
medline:
12
10
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. For advanced HCC, sorafenib was considered the standard of care for more than ten years. Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune checkpoint inhibitors or antiangiogenic therapy. We now review the practical aspects of the atezolizumab and bevacizumab combination, including current evidence, indications, contraindications, management of adverse events, sequencing of this combination, areas of current knowledge gaps and future areas of active clinical research of this combination for busy clinicians in clinical practice.
Identifiants
pubmed: 34630880
doi: 10.4254/wjh.v13.i9.1132
pmc: PMC8473489
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1132-1142Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: None of the authors report any conflict-of-interest.
Références
Liver Cancer. 2020 Apr;9(2):119-137
pubmed: 32399427
Cancer. 2019 Sep 15;125(18):3234-3241
pubmed: 31154669
Vaccines (Basel). 2020 Oct 02;8(4):
pubmed: 33023131
Curr Oncol. 2020 Nov;27(Suppl 3):S144-S151
pubmed: 33343208
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Ann Oncol. 2021 Jun;32(6):801-805
pubmed: 33716105
Nature. 2016 Mar 10;531(7593):253-7
pubmed: 26934227
BMC Cancer. 2019 Aug 13;19(1):795
pubmed: 31409405
Hepatology. 2019 Oct;70(4):1437-1442
pubmed: 30927283
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
BMC Cancer. 2019 Nov 8;19(1):1062
pubmed: 31703571
PLoS One. 2020 Mar 4;15(3):e0229696
pubmed: 32130270
Oncoimmunology. 2021 Feb 8;10(1):1875639
pubmed: 33628621
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
J Hepatocell Carcinoma. 2020 Feb 10;7:11-17
pubmed: 32104669
World J Gastroenterol. 2010 Dec 28;16(48):6046-57
pubmed: 21182219
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540870
J Hepatol. 2021 Apr;74(4):931-943
pubmed: 33248171
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Semin Oncol. 2020 Apr - Jun;47(2-3):103-116
pubmed: 32522380
Cells. 2020 Jun 01;9(6):
pubmed: 32492896
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Hepatology. 2020 Jul;72(1):198-212
pubmed: 31698504
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565
pubmed: 34030131
Lancet Oncol. 2021 Jul;22(7):991-1001
pubmed: 34051880
Gut. 2021 Jan;70(1):204-214
pubmed: 32747413
Acta Radiol. 2008 Jun;49(5):523-9
pubmed: 18568538
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
JAMA Oncol. 2020 Dec 1;6(12):e204930
pubmed: 33090186
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160